Culture Shock In Europe For Perrigo With Branded Consumer Business
This article was originally published in The Tan Sheet
Executive Summary
Less than a month after moving up from president to CEO, John Hendrickson tells analysts during the firm's first-quarter earnings briefing that Perrigo's private label OTC drug business remains strong, with the next launch ready to ship, but growing European branded consumer product sales is more of a long-term goal.
You may also be interested in...
Perrigo Starts Branded Consumer Product Rescue Mission In Belgium
Perrigo is restructuring its OTC drug and nutritional product businesses in Belgium – Omega Pharma Belgium NV, Etixx NV and Biover NV – and expects changes will eliminate between 45 and 80 jobs.
Perrigo Starts Branded Consumer Product Rescue Mission In Belgium
Perrigo is restructuring its OTC drug and nutritional product businesses in Belgium – Omega Pharma Belgium NV, Etixx NV and Biover NV – and expects changes will eliminate between 45 and 80 jobs.
Perrigo Wants Answers From Former Owner Of Its Branded Consumer Business
Perrigo reported a $804m impairment for its European branded OTC drug and nutritional products business for the July-September period and will file an arbitration claim against its former owners. Company also highlights Rx-to-OTC switch opportunities.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: